Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03799900

Organisation Name: Naurex, Inc, an affiliate of Allergan plc

Overal Status: Completed

Start Date: November 1, 2018

Last Update: May 16, 2019

Lead Sponsor: Naurex, Inc, an affiliate of Allergan plc

Brief Summary: Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Conditions:
  • Human Abuse Potential


Total execution time in seconds: 0.13662695884705